Full List Of Stories
Commodities were unwanted at the start of the week, led by a drop in energy futures as hurricane Barry moved inland from the Gulf of Mexico and amid GDP data in China showing that the economy slowed to a year-on-year pace of 6. 2% over the three months to June - its slowest clip since 1992 - after expanding by 6. 4% in the first quarter.
These were the movements in some of the most widely-followed 10-year sovereign bond yields:.
Miners and industrial metals names paced gains at the start of the week, boosted by a slate of solid economic data out China referencing the month of June.
The market spotlight on Tuesday will shift towards the US, with a barrage of economic and corporate reports scheduled for release.
Stocks on the Continent overcame early selling, helped by solid readings on Chinese economic activity in June, after Germany's ministry of Economics warned of softness ahead in the country's services sector.
London stocks ticked higher on Monday as investors mulled mixed Chinese economic data and the start of the US second quarter earnings season as banking giant delivered a solid score card for the three months to June.
Analysts at JP Morgan reiterated their 'overweight' stance on shares of software maker Sophos, telling clients that the reacceleration in billings over the first quarter of the new fiscal year supported confidence in the medium-term thesis for the stock.
Factory sector activity in the New York area picked up a tad more quickly than expected in July, following a sharp drop during the previous month, according to the results of a closely-followed survey.
Markets' focus over the coming week will be on the US corporate results season.
Stocks on the Continent are trading on a slightly mixed note at the start of the week, with a warning of softness ahead in services sector activity from the German ministry of Economics dampening investor sentiment.
Gilead Sciences will pay over $5. 0bn for the exclusive licence and options rights to Belgian-Dutch biotechnology outfit Galapagos's entire pipeline of potential drugs outside of Europe.